Literature DB >> 23319766

Mechanisms of resistance to PARP inhibitors--three and counting.

Tito Fojo1, Susan Bates.   

Abstract

Given the malleable nature of cancer cells, we should expect, and do see, the development of resistance to any new chemotherapeutic agent. Models that help us understand how this happens are a first step to better and more effective chemotherapeutics.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23319766      PMCID： PMC6936267          DOI： 10.1158/2159-8290.CD-12-0514

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  16 in total

Review 1.  Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights.

Authors:  Reinhard Dummer; Keith T Flaherty
Journal:  Curr Opin Oncol       Date:  2012-03       Impact factor: 3.645

2.  A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas.

Authors:  Shivaani Kummar; Jiuping Ji; Robert Morgan; Heinz-Josef Lenz; Shannon L Puhalla; Chandra P Belani; David R Gandara; Deborah Allen; Brian Kiesel; Jan H Beumer; Edward M Newman; Larry Rubinstein; Alice Chen; Yiping Zhang; Lihua Wang; Robert J Kinders; Ralph E Parchment; Joseph E Tomaszewski; James H Doroshow
Journal:  Clin Cancer Res       Date:  2012-02-03       Impact factor: 12.531

3.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.

Authors:  M William Audeh; James Carmichael; Richard T Penson; Michael Friedlander; Bethan Powell; Katherine M Bell-McGuinn; Clare Scott; Jeffrey N Weitzel; Ana Oaknin; Niklas Loman; Karen Lu; Rita K Schmutzler; Ursula Matulonis; Mark Wickens; Andrew Tutt
Journal:  Lancet       Date:  2010-07-06       Impact factor: 79.321

4.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.

Authors:  Andrew Tutt; Mark Robson; Judy E Garber; Susan M Domchek; M William Audeh; Jeffrey N Weitzel; Michael Friedlander; Banu Arun; Niklas Loman; Rita K Schmutzler; Andrew Wardley; Gillian Mitchell; Helena Earl; Mark Wickens; James Carmichael
Journal:  Lancet       Date:  2010-07-06       Impact factor: 79.321

Review 5.  Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer.

Authors:  Christina M Annunziata; Joyce O'Shaughnessy
Journal:  Clin Cancer Res       Date:  2010-09-07       Impact factor: 12.531

6.  Distinct roles of chromatin-associated proteins MDC1 and 53BP1 in mammalian double-strand break repair.

Authors:  Anyong Xie; Andrea Hartlerode; Manuel Stucki; Shobu Odate; Nadine Puget; Amy Kwok; Ganesh Nagaraju; Catherine Yan; Frederick W Alt; Junjie Chen; Stephen P Jackson; Ralph Scully
Journal:  Mol Cell       Date:  2007-12-28       Impact factor: 17.970

7.  Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer.

Authors:  Marina Pajic; Jayasree K Iyer; Ariena Kersbergen; Eline van der Burg; Anders O H Nygren; Jos Jonkers; Piet Borst; Sven Rottenberg
Journal:  Cancer Res       Date:  2009-08-04       Impact factor: 12.701

8.  Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

Authors:  Janneke E Jaspers; Ariena Kersbergen; Ute Boon; Wendy Sol; Liesbeth van Deemter; Serge A Zander; Rinske Drost; Ellen Wientjens; Jiuping Ji; Amal Aly; James H Doroshow; Aaron Cranston; Niall M B Martin; Alan Lau; Mark J O'Connor; Shridar Ganesan; Piet Borst; Jos Jonkers; Sven Rottenberg
Journal:  Cancer Discov       Date:  2012-10-25       Impact factor: 39.397

9.  Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer.

Authors:  Sven Rottenberg; Anders O H Nygren; Marina Pajic; Fijs W B van Leeuwen; Ingrid van der Heijden; Koen van de Wetering; Xiaoling Liu; Karin E de Visser; Kenneth G Gilhuijs; Olaf van Tellingen; Jan P Schouten; Jos Jonkers; Piet Borst
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-11       Impact factor: 11.205

10.  Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

Authors:  Junko Murai; Shar-yin N Huang; Benu Brata Das; Amelie Renaud; Yiping Zhang; James H Doroshow; Jiuping Ji; Shunichi Takeda; Yves Pommier
Journal:  Cancer Res       Date:  2012-11-01       Impact factor: 13.312
View more
  29 in total

1.  EGFR and c-MET Cooperate to Enhance Resistance to PARP Inhibitors in Hepatocellular Carcinoma.

Authors:  Qiongzhu Dong; Yi Du; Hui Li; Chunxiao Liu; Yongkun Wei; Mei-Kuang Chen; Xixi Zhao; Yu-Yi Chu; Yufan Qiu; Lunxiu Qin; Hirohito Yamaguchi; Mien-Chie Hung
Journal:  Cancer Res       Date:  2018-12-20       Impact factor: 12.701

Review 2.  Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?

Authors:  Narjust Duma; Kelly C Gast; Grace M Choong; Roberto A Leon-Ferre; Ciara C O'Sullivan
Journal:  Curr Oncol Rep       Date:  2018-06-08       Impact factor: 5.075

3.  Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.

Authors:  H S Han; V Diéras; M Robson; M Palácová; P K Marcom; A Jager; I Bondarenko; D Citrin; M Campone; M L Telli; S M Domchek; M Friedlander; B Kaufman; J E Garber; Y Shparyk; E Chmielowska; E H Jakobsen; V Kaklamani; W Gradishar; C K Ratajczak; C Nickner; Q Qin; J Qian; S P Shepherd; S J Isakoff; S Puhalla
Journal:  Ann Oncol       Date:  2018-01-01       Impact factor: 32.976

4.  Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer.

Authors:  Lebaron C Agostini; Grace A McCarthy; Aditi Jain; Saswati N Chand; AnnJosette Ramirez; Avinoam Nevler; Joseph Cozzitorto; Christopher W Schultz; Cinthya Yabar Lowder; Kate M Smith; Ian D Waddell; Maria Raitses-Gurevich; Chani Stossel; Yulia Glick Gorman; Dikla Atias; Charles J Yeo; Jordan M Winter; Kenneth P Olive; Talia Golan; Michael J Pishvaian; Donald Ogilvie; Dominic I James; Allan M Jordan; Jonathan R Brody
Journal:  Cancer Res       Date:  2019-07-04       Impact factor: 12.701

5.  Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.

Authors:  Junko Murai; Yiping Zhang; Joel Morris; Jiuping Ji; Shunichi Takeda; James H Doroshow; Yves Pommier
Journal:  J Pharmacol Exp Ther       Date:  2014-03-20       Impact factor: 4.030

Review 6.  Progress in the treatment of ovarian cancer-lessons from homologous recombination deficiency-the first 10 years.

Authors:  S B Kaye
Journal:  Ann Oncol       Date:  2016-04       Impact factor: 32.976

7.  Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer.

Authors:  Gamze Guney Eskiler; Gulsah Cecener; Unal Egeli; Berrin Tunca
Journal:  Pharm Res       Date:  2018-09-25       Impact factor: 4.200

Review 8.  An update on PARP inhibitors--moving to the adjuvant setting.

Authors:  Amir Sonnenblick; Evandro de Azambuja; Hatem A Azim; Martine Piccart
Journal:  Nat Rev Clin Oncol       Date:  2014-10-07       Impact factor: 66.675

Review 9.  Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.

Authors:  Angela George; Stan Kaye; Susana Banerjee
Journal:  Nat Rev Clin Oncol       Date:  2016-12-13       Impact factor: 66.675

10.  Synthesis of 2,3-dihydrobenzo[b][1,4]dioxine-5-carboxamide and 3-oxo-3,4-dihydrobenzo[b][1,4]oxazine-8-carboxamide derivatives as PARP1 inhibitors.

Authors:  Xuwei Shao; Steven Pak; Uday Kiran Velagapudi; Shruthi Gobbooru; Sai Shilpa Kommaraju; Woon-Kai Low; Gopal Subramaniam; Sanjai Kumar Pathak; Tanaji T Talele
Journal:  Bioorg Chem       Date:  2020-07-08       Impact factor: 5.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.